罗氏万赛维去哪买？

(Valganciclovir Hydrochloride Tablets) was developed mainly to prevent cytomegalovirus (CMV) infection. Oral valganciclovir has replaced oral or intravenous ganciclovir and has become the first choice for preventing CMV in patients using immunosuppressants. In March 2001, Vancevir was approved by the US FDA, and was first marketed in the United States in May 2001 for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. The drug has since become the first oral treatment for CMV retinitis in patients with immunodeficiency syndrome (AIDS). In May 2003, Vancevir was again approved by the FDA for the prevention and treatment of secondary CMV infection in organ transplant recipients.

So far, valcyte has been launched in the United States, China, Turkey and other countries and regions, where patients can buy the drugs they need. For domestic patients, although the drug has been on the domestic market for more than ten years, it has not yet been included in the scope of medical insurance. If a patient purchases a box of Vancevi, which is sold in China, it will cost about $17,000. The drug specification is 450mg*60 tablets/box, which is a considerable financial burden for patients. In order to reduce the burden, patients can obtain more cost-effective drugs from overseas through medical companion travel.

According to Medical Companion Travel, a box of the Turkish version of Vancevi is priced at about $3,000, and the drug specifications are also 450mg*60 tablets/box. Domestic patients who need this version of medicine can either go abroad to purchase it in person or obtain their specific drug purchase channels through medical companion travel. Through this purchasing method, patients can purchase genuine and good medicines without leaving home.

As the world's largest biotechnology company, Roche provides a variety of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories around the world, which is one of its important products.

Recommended hot articles: /newsDetail/90797.html